ADVERTISEMENT
CMS Approves NTAP for Symplicity Spyral RDN System
Medtronic News
CMS posted its FY25 Inpatient Prospective Payment System (IPPS) Final Rule, which covers the New Technology Add-on Payment (NTAP) program. In the final rule, CMS approved NTAP for the Symplicity Spyral™ catheter. The NTAP will go into effect on October 1, 2024, and will be in place for three years.
The NTAP payment program supports access for newly approved, innovative technologies where the cost to adopt may inhibit patient access. This includes devices granted Breakthrough Device designations from the FDA like the Symplicity Spyral™ renal denervation system.
“Medtronic is pleased to see the final rule for the Medtronic Symplicity Spyral application for NTAP,” said Jason Weidman, SVP and president of the Coronary and Renal Denervation business in the Medtronic Cardiovascular portfolio. “Although we expect a small number of inpatient renal denervation procedures, this a notable milestone in developing reimbursement for Symplicity Spyral.”
Find More:
Cardiovascular Ambulatory Surgery Centers (ASCs) Topic Center
The Latest Clinical & Industry News
Case Reports
Grand Rounds With Morton Kern, MD
